Synovial Sarcoma Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Advenchen Laboratories, Ipsen, Daiichi Sankyo, EpiZyme Inc, Merck & Co

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Synovial Sarcoma pipeline constitutes 15+ key companies continuously working towards developing 20+ Synovial Sarcoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Synovial Sarcoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Synovial Sarcoma Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Synovial Sarcoma Market.

Some of the key takeaways from the Synovial Sarcoma Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Synovial Sarcoma treatment therapies with a considerable amount of success over the years.

*
Synovial Sarcoma companies working in the treatment market are Advenchen Laboratories, Ipsen, Daiichi Sankyo, OncoTherapy Science, Foghorn Therapeutics, BioAtla, Inc., Takara Bio, C4 Therapeutics, Adaptimmune, Epizyme, Inc., and others, are developing therapies for the Synovial Sarcoma treatment

*
Emerging Synovial Sarcoma therapies in the different phases of clinical trials are- AL3818, Tazemetostat, DS-2243a, OTSA101, FHD-609, CAB-AXL-ADC, NY-ESO-1, CFT - 8634, Afamitresgene autoleucel, Tazemetostat, and others are expected to have a significant impact on the Synovial Sarcoma market in the coming years.

*
In June 2025, Updated results from the phase 1b/2 MB-107 trial (NCT04887298) revealed that the next-generation anthracycline analog annamycin showed clinical activity and a favorable safety profile in patients with soft tissue sarcoma and lung metastases.

*
In June 2025, According to a news release from its developer, QBiotics Group Limited, intratumoral tigilanol tiglate showed promising efficacy in a small group of patients with advanced and/or metastatic soft tissue sarcomas (STSs) in the phase 2a QB46C-H07 trial (NCT05755113).

*
In May 2025, Data from a phase 2 trial (NCT03951571) published in Clinical Cancer Research showed that adjuvant treatment with anlotinib reduced the risk of disease recurrence compared with surgery alone in patients with completely resected localized, high-grade soft tissue sarcoma.

*
In May 2025, According to a news release from its developer, Thermosome, the FDA has granted orphan drug designation (ODD) to THE001 (DPPG2-TSL-DOX), a thermosensitive liposomal formulation of doxorubicin, for treating patients with soft tissue sarcoma (STS).

*
In December 2024, Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company focused on transforming solid tumor cancer treatment with cell therapy, announced that the first patient has been treated with TECELRA Registered (afamitresgene autoleucel). TECELRA is the first engineered cell therapy approved in the U.S. for solid tumors and marks the first new treatment option in over a decade for synovial sarcoma, a rare soft tissue cancer primarily affecting young adults.

*
In November 2024, Adaptimmune's pivotal Phase II trial of its investigational T cell therapy, lete-cel, has achieved its primary endpoint, positioning the company for a second sarcoma approval. The UK-based biotech plans to submit a rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) by the end of 2025 for lete-cel's use in treating advanced or metastatic synovial sarcoma and myxoid/round cell liposarcoma (MRCLS).

Synovial Sarcoma Overview

Synovial Sarcoma is a rare and aggressive type of soft tissue cancer that typically occurs near the joints of the arms or legs, but it can also develop in other parts of the body. Despite its name, it does not arise from synovial tissue but from mesenchymal cells. It most often affects adolescents and young adults. Symptoms may include a painless lump, swelling, or restricted joint movement. Synovial sarcoma is associated with a specific genetic mutation involving the SS18-SSX gene fusion. Treatment usually includes surgery, radiation therapy, and chemotherapy. Early diagnosis and treatment are crucial for improving outcomes.

Get a Free Sample PDF Report to know more about Synovial Sarcoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/synovial-sarcoma-pipeline-insight [https://www.delveinsight.com/report-store/synovial-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Synovial Sarcoma Drugs Under Different Phases of Clinical Development Include:

*
AL3818: Advenchen Laboratories

*
Tazemetostat: Ipsen

*
DS-2243a: Daiichi Sankyo

*
OTSA101: OncoTherapy Science

*
FHD-609: Foghorn Therapeutics

*
CAB-AXL-ADC: BioAtla, Inc.

*
NY-ESO-1: Takara Bio

*
CFT - 8634: C4 Therapeutics

*
Afamitresgene autoleucel: Adaptimmune

*
Tazemetostat: Epizyme, Inc.

Synovial Sarcoma Route of Administration

Synovial Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Synovial Sarcoma Molecule Type

Synovial Sarcoma Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Synovial Sarcoma Pipeline Therapeutics Assessment

*
Synovial Sarcoma Assessment by Product Type

*
Synovial Sarcoma By Stage and Product Type

*
Synovial Sarcoma Assessment by Route of Administration

*
Synovial Sarcoma By Stage and Route of Administration

*
Synovial Sarcoma Assessment by Molecule Type

*
Synovial Sarcoma by Stage and Molecule Type

DelveInsight's Synovial Sarcoma Report covers around 20+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Synovial Sarcoma product details are provided in the report. Download the Synovial Sarcoma pipeline report to learn more about the emerging Synovial Sarcoma therapies [https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Synovial Sarcoma Therapeutics Market include:

Key companies developing therapies for Synovial Sarcoma are - EpiZyme Inc, Merck & Co., Inc, Immunocore Ltd, Johnson & Johnson Private Limited, Karyopharm Therapeutics Inc, Novartis AG, Pfizer Inc, F. Hoffmann-La Roche Ltd, Bayer AG, Epizyme, Cue Biopharma, Eli Lilly and Company, Adaptimmune Therapeutics Plc, Advenchen Laboratories LLC, Takara Bio Inc, and others.

Synovial Sarcoma Pipeline Analysis:

The Synovial Sarcoma pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Synovial Sarcoma with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Synovial Sarcoma Treatment.

*
Synovial Sarcoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Synovial Sarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Synovial Sarcoma market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Synovial Sarcoma drugs and therapies [https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Synovial Sarcoma Pipeline Market Drivers

*
Increasing Incidence of Synovial Sarcoma, increasing research and development activities for the development of targeted therapies are some of the important factors that are fueling the Synovial Sarcoma Market.

Synovial Sarcoma Pipeline Market Barriers

*
However, lack of approved therapies, adverse effects associated with the drugs and other factors are creating obstacles in the Synovial Sarcoma Market growth.

Scope of Synovial Sarcoma Pipeline Drug Insight

*
Coverage: Global

*
Key Synovial Sarcoma Companies: Advenchen Laboratories, Ipsen, Daiichi Sankyo, OncoTherapy Science, Foghorn Therapeutics, BioAtla, Inc., Takara Bio, C4 Therapeutics, Adaptimmune, Epizyme, Inc., and others

*
Key Synovial Sarcoma Therapies: AL3818, Tazemetostat, DS-2243a, OTSA101, FHD-609, CAB-AXL-ADC, NY-ESO-1, CFT - 8634, Afamitresgene autoleucel, Tazemetostat, and others

*
Synovial Sarcoma Therapeutic Assessment: Synovial Sarcoma current marketed and Synovial Sarcoma emerging therapies

*
Synovial Sarcoma Market Dynamics: Synovial Sarcoma market drivers and Synovial Sarcoma market barriers

Request for Sample PDF Report for Synovial Sarcoma Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Synovial Sarcoma Report Introduction

2. Synovial Sarcoma Executive Summary

3. Synovial Sarcoma Overview

4. Synovial Sarcoma- Analytical Perspective In-depth Commercial Assessment

5. Synovial Sarcoma Pipeline Therapeutics

6. Synovial Sarcoma Late Stage Products (Phase II/III)

7. Synovial Sarcoma Mid Stage Products (Phase II)

8. Synovial Sarcoma Early Stage Products (Phase I)

9. Synovial Sarcoma Preclinical Stage Products

10. Synovial Sarcoma Therapeutics Assessment

11. Synovial Sarcoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Synovial Sarcoma Key Companies

14. Synovial Sarcoma Key Products

15. Synovial Sarcoma Unmet Needs

16 . Synovial Sarcoma Market Drivers and Barriers

17. Synovial Sarcoma Future Perspectives and Conclusion

18. Synovial Sarcoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=synovial-sarcoma-pipeline-2025-fda-approvals-therapies-clinical-trials-and-latest-developments-unveiled-by-delveinsight-advenchen-laboratories-ipsen-daiichi-sankyo-epizyme-inc-merck-co]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.